Jinyuan Wang

Jinyuan Wang

Auto-generated profile, based on publicly available information

Jinyuan Wang

Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital Eye Center, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in The Lancet Regional Health - Western Pacific
Verified
Journal Article
Open access
ZPZhe Pan
Zhe Pan
HXHaocheng Xian
Haocheng Xian
FLFeng Li
Feng Li
ZWZiyao Wang
Ziyao Wang
ZLZihan Li
Zihan Li
TWTien Yin Wong
Tien Yin Wong
The global rise in myopia, particularly in Asia, presents significant public health challenges. Analyzing trends and forecasting impacts are critical for developing strategies to mitigate this burden. We conducted the largest study to date on myopia and high myopia prevalence in Chinese children and adolescents aged 7-18 years, analyzing data from 5,095,256 individuals across 119 studies from 1998 to 2022. Data variability between cycloplegia and non-cycloplegia measurements was addressed using a distance-based model averaging calibration. Aggregated prevalence and age-specific urban-rural trends were estimated using thin plate spline regression, with projections to 2050 derived from time series modeling. Myopia prevalence plateaued in 2006 in urban areas and in 2013 in rural areas, with the urban-rural prevalence gap narrowing since 2015 (urban/rural ratio below 1.3 for all ages). By 2050, myopia prevalence is projected to stabilize at 27.1% (95% CI: 10.0-44.4%) for ages 7-9 and 81.5% (74.7-88.3%) for ages 16-18 in urban areas, and at 20.1% (8.6-31.7%) and 74.1% (63.2-84.8%), respectively, in rural areas. High myopia prevalence among adolescents aged 16-18 is expected to rise from 7.3% in 2001 to 22.1% by 2050. Prevalence correlated significantly with the Human Development Index (P < 0.001). Despite stabilization in overall myopia prevalence, the continued rise in high myopia underscores the need for targeted control measures. Projections emphasize the importance of addressing regional disparities and prioritizing public health interventions. National Natural Science Foundation of China (#82271086; #82388101; #72495123).

24 April 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JWJinyuan Wang
Jinyuan Wang
JZJinlu Zhang
Jinlu Zhang
SYShicheng Yu
Shicheng Yu
HLHongyan Li
Hongyan Li
SCShaohong Chen
Shaohong Chen
WWWenbin Wei
Wenbin Wei
Bietti crystalline corneoretinal dystrophy is an inherited retinal disease caused by mutations in CYP4V2, which results in blindness in the working-age population, and there is currently no available treatment. Here, we report the results of the first-in-human clinical trial (NCT04722107) of gene therapy for Bietti crystalline corneoretinal dystrophy, including 12 participants who were followed up for 180–365 days. This open-label, single-arm exploratory trial aimed to assess the safety and efficacy of a recombinant adeno-associated-virus-serotype-2/8 vector encoding the human CYP4V2 protein (rAAV2/8-hCYP4V2). Participants received a single unilateral subretinal injection of 7.5 × 1010 vector genomes of rAAV2/8-hCYP4V2. Overall, 73 treatment-emergent adverse events were reported, with the majority (98.6%) being of mild or moderate intensity and considered to be procedure- or corticosteroid-related; no treatment-related serious adverse events or local/systemic immune toxicities were observed. Compared with that measured at baseline, 77.8% of the treated eyes showed improvement in best-corrected visual acuity (BCVA) on day 180, with a mean ± standard deviation increase of 9.0 ± 10.8 letters in the 9 eyes analyzed (p = 0.021). By day 365, 80% of the treated eyes showed an increase in BCVA, with a mean increase of 11.0 ± 10.6 letters in the 5 eyes assessed (p = 0.125). Importantly, the patients’ improvement observed using multifocal electroretinogram, microperimetry, and Visual Function Questionnaire-25 further supported the beneficial effects of the treatment. We conclude that the favorable safety profile and visual improvements identified in this trial encourage the continued development of rAAV2/8-hCYP4V2 (named ZVS101e).

7 November 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JWJinyuan Wang
Jinyuan Wang
SZShun Zhang
Shun Zhang
LHLinlin Hu
Linlin Hu
YWYan Wang
Yan Wang
KLKe Liu
Ke Liu
XLXiaocan Lei
Xiaocan Lei
Abnormal lipid metabolism and chronic low-grade inflammation are the main traits of obesity. Especially, the molecular mechanism of concomitant deficiency in steroidogenesis-associated enzymes related to testosterone (T) synthesis of obesity dominated a decline in male fertility is still poorly understood. Here, we found that in vivo, supplementation of pyrroloquinoline quinone (PQQ) efficaciously ameliorated the abnormal lipid metabolism and testicular spermatogenic function from high-fat-diet (HFD)-induced obese mice. Moreover, the transcriptome analysis of the liver and testicular showed that PQQ supplementation not only inhibited the high expression of proprotein convertase subtilisin/Kexin type 9 (PCSK9) but also weakened the NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated pyroptosis, which both played a negative role in T synthesis of Leydig Cells (LCs). Eventually, the function and the pyroptosis of LCs cultured with palmitic acid in vitro were simultaneously benefited by suppressing the expression of NLRP3 or PCSK9 respectively, as well the parallel effects of PQQ were affirmed. Collectively, our data revealed that PQQ supplementation is a feasible approach to protect T synthesis from PCSK9-NLRP3 crosstalk-induced LCs’ pyroptosis in obese men.

1 November 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
PWPing Wang
Ping Wang
XYXuan Yang
Xuan Yang
NZNan Zhou
Nan Zhou
JWJinyuan Wang
Jinyuan Wang
YLYang Li
Yang Li
WWWenbin Wei
Wenbin Wei
Purpose: Uveal melanoma (UM) is a primary intraocular tumor in adults, with a high percentage of metastases to the liver. Identifying potential key genes may provide information for early detection and prognosis of UM metastasis. Patients and Methods: Differentially expressed genes (DEGs) were identified using the GSE22138 dataset. Weighted gene co-expression network analysis was used to construct co-expression modules. Functional enrichment analysis was performed for DEGs and genes of key modules. Hub genes were screened by co-expression network and protein–protein interaction network (PPI), and validated by survival analysis in The Cancer Genome Atlas database. Gene set enrichment analysis (GSEA) was used to explore the potential metastasis mechanism of UM. Transient transfection was used to investigate the effect of TIMP1 on the proliferation, migration, and invasion of UM cells. Results: In total, 552 DEGs were identified between primary and metastatic UM and mainly enriched in extracellular matrix, cellular senescence and focal adhesion pathway. A weighted gene co‑expression network was built to identify key gene modules associated with UM metastasis (n=36). The turquoise module is positively correlated with metastasis and genes in this module were mainly enriched in peptidyl-tyrosine autophosphorylation and regulation of organ growth. The hub gene TIMP1 was screened out by co-expression network and PPI analysis. High expression of TIMP1 was related to p53 pathway by GSEA and short overall survival time. Experimental results indicated that overexpression of TIMP1 inhibited the proliferation and migration, while it had no significant effect on invasion of UM cells. Conclusion: Our study indicates that TIMP1 might be associated with metastasis in UM, which might have important significance for identifying patients with high risk of metastasis and predicting the prognosis of UM.

26 February 2026 in The Lancet Digital Health
Verified
Journal Article
Open access
HCHaichao Chen
Haichao Chen
ZZZhengyun Zhao
Zhengyun Zhao
SZSongchi Zhou
Songchi Zhou
SHShikai Hu
Shikai Hu
JWJinyuan Wang
Jinyuan Wang
TWTien Yin Wong
Tien Yin Wong
Rare diseases pose a substantial clinical and public health burden, with timely and accurate diagnoses remaining a formidable challenge in many countries and settings. Large language models (LLMs) have the potential to enhance the screening and diagnosis of rare diseases. However, existing evaluations of such capacities of LLMs are insufficient due to the low sample sizes, poor coverage of different rare diseases, and weak real-world clinical relevance. To address these issues, we developed an automated data collection pipeline, RareArena, to curate a comprehensive rare disease dataset from PubMed Central case reports. Two tasks were considered: rare disease screening (RDS), which involved rare disease recognition before confirmatory diagnostic tests; and rare disease confirmation (RDC), which required diagnosis with complete information. The constructed RDS task comprised 49 760 cases of 4597 rare diseases, whereas the RDC task comprised 22 901 cases of 3522 rare diseases. Human evaluations by two physicians across three dimensions-leakage, fidelity, and complexity-validated the high quality of our dataset. We systematically benchmarked ten state-of-the-art LLMs of varying sizes (GPT-4o, Llama3·1-70B, Llama3·1-8B, Qwen2·5-72B, Qwen2·5-7B, Gemma2-9B, Phi3-7B, Llama3-70B-UltraMedical, Llama3-8B-UltraMedical, and MedLlama-7B) and found that GPT-4o achieved the best performance in both the tasks (RDS: 33·1% top-1 recall, 56·9% top-5 recall; RDC: 64·2% top-1 recall, 85·9% top-5 recall). Additionally, GPT-4o performed better on genetically inherited diseases than on non-genetically inherited diseases in both the tasks, with its highest performance observed in systemic or rheumatologic diseases (RDS: 48·5% top-1 recall, 76·5% top-5 recall; RDC: 76·0% top-1 recall, 93·5% top-5 recall). To our knowledge, our dataset represents the largest rare disease diagnostic benchmark to date, featuring broad and deep disease coverage and reflecting clinically relevant scenarios. RareArena highlights the potential of LLMs in rare disease screening and diagnosis, providing a foundation for improved care for individuals with rare diseases around the world.

24 July 2026 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HJHuixun Jia
Huixun Jia
BQBo Qian
Bo Qian
YQYanlin Qu
Yanlin Qu
JWJinyuan Wang
Jinyuan Wang
JCJieqiong Chen
Jieqiong Chen
Xiaodong SunXiaodong Sun
Xiaodong Sun